TR200001059T2 - Kazanılmış protein C eksikliği veya hiper pıhtılaşma durumlarının tedavisi. - Google Patents
Kazanılmış protein C eksikliği veya hiper pıhtılaşma durumlarının tedavisi.Info
- Publication number
- TR200001059T2 TR200001059T2 TR2000/01059T TR200001059T TR200001059T2 TR 200001059 T2 TR200001059 T2 TR 200001059T2 TR 2000/01059 T TR2000/01059 T TR 2000/01059T TR 200001059 T TR200001059 T TR 200001059T TR 200001059 T2 TR200001059 T2 TR 200001059T2
- Authority
- TR
- Turkey
- Prior art keywords
- hypercoagulation
- treatment
- acquired
- deficiency
- sepsis
- Prior art date
Links
- 206010020608 Hypercoagulation Diseases 0.000 title abstract 2
- 230000003027 hypercoagulation Effects 0.000 title abstract 2
- 208000014171 autosomal dominant thrombophilia due to protein C deficiency Diseases 0.000 title 1
- 206010001052 Acute respiratory distress syndrome Diseases 0.000 abstract 1
- 101710117545 C protein Proteins 0.000 abstract 1
- 206010027280 Meningococcal sepsis Diseases 0.000 abstract 1
- 101800004937 Protein C Proteins 0.000 abstract 1
- 208000008425 Protein deficiency Diseases 0.000 abstract 1
- 102100036546 Salivary acidic proline-rich phosphoprotein 1/2 Human genes 0.000 abstract 1
- 101800001700 Saposin-D Proteins 0.000 abstract 1
- 206010040047 Sepsis Diseases 0.000 abstract 1
- 201000000028 adult respiratory distress syndrome Diseases 0.000 abstract 1
- 210000001185 bone marrow Anatomy 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 208000014674 injury Diseases 0.000 abstract 1
- 230000035935 pregnancy Effects 0.000 abstract 1
- 229960000856 protein c Drugs 0.000 abstract 1
- 201000005380 purpura fulminans Diseases 0.000 abstract 1
- 238000001356 surgical procedure Methods 0.000 abstract 1
- 229940124597 therapeutic agent Drugs 0.000 abstract 1
- 238000002054 transplantation Methods 0.000 abstract 1
- 230000008733 trauma Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
- A61K38/482—Serine endopeptidases (3.4.21)
- A61K38/4866—Protein C (3.4.21.69)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/02—Nutrients, e.g. vitamins, minerals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
- C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
- C12N9/6424—Serine endopeptidases (3.4.21)
- C12N9/6464—Protein C (3.4.21.69)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
- C12Y304/21—Serine endopeptidases (3.4.21)
- C12Y304/21069—Protein C activated (3.4.21.69)
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Biochemistry (AREA)
- Biomedical Technology (AREA)
- General Engineering & Computer Science (AREA)
- Gastroenterology & Hepatology (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Pulmonology (AREA)
- Nutrition Science (AREA)
- Dermatology (AREA)
- Obesity (AREA)
- Reproductive Health (AREA)
- Endocrinology (AREA)
- Surgery (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Sepsis, purpura fulminans, meningokokal sepsis, kemik iligi ve diger transplantasyonlar, ciddi yaniklar, gebelik, büyük ameliyatlar, ciddi travmalar ya da ARDS ile ortaya çikan kazanilmis C proteini eksikligi ya da kazanilmis hiper pihtilasma halinden musdarip insan hastalarin tedavisi olup, bu tedavi, kanama komplikasyonlarina neden olmak için düsük bir potansiyeli olan yüksek ölçüde seçici bir terapötik maddenin temin edilmesiyle aktive C proteininin kullanimini içermektedir.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US6254997P | 1997-10-20 | 1997-10-20 | |
| US6476597P | 1997-11-07 | 1997-11-07 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| TR200001059T2 true TR200001059T2 (tr) | 2000-10-23 |
Family
ID=26742406
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| TR2000/01059T TR200001059T2 (tr) | 1997-10-20 | 1998-10-14 | Kazanılmış protein C eksikliği veya hiper pıhtılaşma durumlarının tedavisi. |
Country Status (27)
| Country | Link |
|---|---|
| US (7) | US6037322A (tr) |
| EP (2) | EP0913156B1 (tr) |
| JP (2) | JP3805981B2 (tr) |
| KR (1) | KR100798174B1 (tr) |
| CN (1) | CN1276726A (tr) |
| AT (1) | ATE292979T1 (tr) |
| AU (1) | AU748417B2 (tr) |
| BR (1) | BR9812965A (tr) |
| CA (1) | CA2306983A1 (tr) |
| DE (1) | DE69829721T2 (tr) |
| DK (1) | DK0913156T3 (tr) |
| EA (1) | EA002496B1 (tr) |
| ES (1) | ES2239382T3 (tr) |
| HU (2) | HUP0001237A3 (tr) |
| ID (1) | ID24901A (tr) |
| IL (2) | IL135712A0 (tr) |
| MY (1) | MY117655A (tr) |
| NO (1) | NO20002005L (tr) |
| NZ (1) | NZ504026A (tr) |
| PL (1) | PL200515B1 (tr) |
| PT (1) | PT913156E (tr) |
| SI (1) | SI0913156T1 (tr) |
| TR (1) | TR200001059T2 (tr) |
| TW (1) | TWI225404B (tr) |
| UA (1) | UA72194C2 (tr) |
| WO (1) | WO1999020293A1 (tr) |
| ZA (1) | ZA989385B (tr) |
Families Citing this family (73)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ZA983497B (en) | 1997-04-28 | 1999-10-25 | Lilly Co Eli | Activated protein c formulations. |
| US6630137B1 (en) | 1997-04-28 | 2003-10-07 | Eli Lilly And Company | Activated protein C formulations |
| HUP0001237A3 (en) * | 1997-10-20 | 2002-01-28 | Lilly Co Eli | Methods for treating vascular disorders |
| EP1138692A1 (en) | 2000-03-29 | 2001-10-04 | Erasmus Universiteit Rotterdam | Fragments of human chorionic gonadotropin (hcg) as immunoregulator |
| US20050227925A1 (en) * | 2004-04-08 | 2005-10-13 | Robbert Benner | Compositions capable of reducing elevated blood urea concentration |
| US8680059B2 (en) | 1998-05-20 | 2014-03-25 | Biotempt B.V. | Oligopeptide acetate and formulations thereof |
| US6844315B2 (en) * | 1998-05-20 | 2005-01-18 | Erasmus Universiteit Rotterdam | Immunoregulator |
| US7175679B2 (en) * | 2001-03-29 | 2007-02-13 | Biotempt B.V. | Oligopeptide treatment of NF-κB mediated inflammation |
| US20030220258A1 (en) | 2001-12-21 | 2003-11-27 | Robbert Benner | Treatment of ischemic events |
| US20040202645A1 (en) * | 2003-04-08 | 2004-10-14 | Khan Nisar Ahmed | Administration of gene-regulatory peptides |
| US6921751B1 (en) * | 1998-05-20 | 2005-07-26 | Erasmus Universiteit Rotterdam | Immunoregulator |
| US6287516B1 (en) | 1998-07-10 | 2001-09-11 | Immunocept, L.L.C. | Hemofiltration systems, methods, and devices used to treat inflammatory mediator related disease |
| US20040199099A1 (en) * | 1998-07-10 | 2004-10-07 | Matson James R | Hemofiltration systems, methods and devices used to treat inflammatory mediator related disease |
| EP1124573A1 (en) | 1998-10-22 | 2001-08-22 | Eli Lilly And Company | Methods for treating sepsis |
| EP1128842B1 (en) * | 1998-11-13 | 2006-03-15 | Eli Lilly And Company | Use of human protein c for the manufacture of a medicament for treating heparin-induced thrombocytopenia |
| IL142247A0 (en) * | 1998-11-23 | 2002-03-10 | Lilly Co Eli | Method of treating sickle cell disease and thalassemia |
| WO2001056532A2 (en) * | 2000-02-04 | 2001-08-09 | The Scripps Research Institute | Neuroprotective, antithrombotic and anti-inflammatory uses of activated protein c (apc) |
| US6736972B1 (en) | 2000-03-24 | 2004-05-18 | Immunocept, L.L.C. | Method and system for providing therapeutic agents with hemofiltration for reducing inflammatory mediator related diseases |
| US8535258B2 (en) * | 2000-03-24 | 2013-09-17 | Immunocept, L.L.C. | Hemofiltration methods for treatment of diseases in a mammal |
| US7291122B2 (en) * | 2000-03-24 | 2007-11-06 | Immunocept, L.L.C. | Hemofiltration methods for treatment of diseases in a mammal |
| US7204981B2 (en) * | 2000-03-28 | 2007-04-17 | Eli Lilly And Company | Methods of treating diseases with activated protein C |
| WO2001072328A2 (en) * | 2000-03-28 | 2001-10-04 | Eli Lilly And Company | Methods of treating diseases with activated protein c |
| US20050037430A1 (en) * | 2000-03-29 | 2005-02-17 | Biotempt B.V. | Methods and uses for protein breakdown products |
| USRE43279E1 (en) | 2000-03-29 | 2012-03-27 | Biotemp B.V. | Compositions capable of reducing elevated blood urea concentration |
| US7358330B2 (en) * | 2001-03-29 | 2008-04-15 | Biotempt B.V. | Immunoregulatory compositions |
| EP1300418A1 (en) * | 2001-10-04 | 2003-04-09 | Erasmus Universiteit Rotterdam | Gene regulation by oligopeptides |
| US7576174B2 (en) * | 2000-03-29 | 2009-08-18 | Biotempt B.V. | Compositions capable of reducing elevated blood urea concentration |
| US8597516B2 (en) * | 2000-05-16 | 2013-12-03 | Immunocept, L.L.C. | Methods and systems for colloid exchange therapy |
| US6787040B2 (en) * | 2000-05-16 | 2004-09-07 | Immunocept, L.L.C. | Method and system for colloid exchange therapy |
| US7087578B2 (en) * | 2000-05-24 | 2006-08-08 | Eli Lilly And Company | Formulations and methods for treating hypercoagulable states |
| WO2002024215A2 (en) * | 2000-09-18 | 2002-03-28 | Eli Lilly And Company | Method for using activated protein c for the treatment of coagulation-associated disorders |
| JP4279554B2 (ja) | 2001-02-19 | 2009-06-17 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング | T細胞エピトープの識別方法および低減された免疫原性を有する分子の製造方法 |
| US20040198652A1 (en) * | 2001-04-24 | 2004-10-07 | Carter J. Paul | Methods and compositions for preventing and treating septic shock and endotoxemia |
| ATE550073T1 (de) * | 2001-06-13 | 2012-04-15 | Univ Sydney | Protein c für die wundheilung |
| EP1417055A4 (en) * | 2001-07-19 | 2007-09-26 | Dmi Biosciences Inc | USE OF COPPER CHELATORS TO PREVENT THE INACTIVATION OF PROTEIN C |
| US20030220259A1 (en) * | 2001-12-21 | 2003-11-27 | Robbert Benner | Treatment of neurological disorders |
| BR0213293A (pt) | 2001-10-15 | 2004-12-21 | Chiron Corp | Uso de tfpi ou de um análogo de tfpi no tratamento de septicemia |
| US20030220261A1 (en) * | 2001-12-21 | 2003-11-27 | Khan Nisar Ahmed | Treatment of iatrogenic disease |
| US20040013661A1 (en) * | 2001-12-21 | 2004-01-22 | Gert Wensvoort | Stratification |
| US20030220260A1 (en) * | 2001-12-21 | 2003-11-27 | Khan Nisar Ahmed | Peptide compositions |
| US20030220257A1 (en) * | 2001-12-21 | 2003-11-27 | Robbert Benner | Treatment of trauma |
| US7560433B2 (en) * | 2001-12-21 | 2009-07-14 | Biotempt B.V. | Treatment of multiple sclerosis (MS) |
| US7501391B2 (en) * | 2001-12-21 | 2009-03-10 | Biotempt B.V. | Treatment of transplant survival |
| US20080318871A1 (en) * | 2001-12-21 | 2008-12-25 | Khan Nisar A | Treatment of neurological disorders |
| US7786084B2 (en) | 2001-12-21 | 2010-08-31 | Biotempt B.V. | Treatment of burns |
| US20030224995A1 (en) * | 2001-12-21 | 2003-12-04 | Khan Nisar Ahmed | Treatment of burns |
| CA2475738A1 (en) * | 2002-03-08 | 2003-09-18 | Eli Lilly And Company | Activated protein c formulations |
| TW200407335A (en) * | 2002-07-22 | 2004-05-16 | Chugai Pharmaceutical Co Ltd | Non-neutralizing antibody to inhibit the inactivation of activated protein C |
| WO2004014315A2 (en) * | 2002-08-13 | 2004-02-19 | Arbios Systems, Inc. | Selective plasma exchange therapy |
| WO2004056309A2 (en) | 2002-12-05 | 2004-07-08 | Socratech L.L.C. | Neuroprotective activity of activated protein c is independent of its anticoagulant activity |
| EP1598368A4 (en) * | 2003-01-20 | 2007-07-25 | Chugai Pharmaceutical Co Ltd | ANTI-PCI neutralizing ANTIBODY |
| US20070142272A1 (en) * | 2003-01-24 | 2007-06-21 | Zlokovic Berislav V | Neuroprotective activity of activated protein c independent of its anticoagulant activity |
| US7517529B2 (en) * | 2003-04-08 | 2009-04-14 | Biotempt B.V. | Treatment of type I diabetes |
| EP2266606B1 (en) | 2003-05-15 | 2014-09-10 | Genentech, Inc. | Methods and compositions for the prevention and treatment of sepsis |
| EP1651252B1 (en) * | 2003-07-08 | 2014-11-26 | The Scripps Research Institute | Activated protein c variants with normal cytoprotective activity but reduced anticoagulant activity |
| US9192657B2 (en) | 2003-07-08 | 2015-11-24 | The Scripps Research Institute | Activated protein C variants with normal cytoprotective activity but reduced anticoagulant activity |
| US20090227669A1 (en) * | 2004-01-23 | 2009-09-10 | The University Of Toledo | Compositions and Methods for Perioperative Bladder Instillation |
| MXPA06010587A (es) * | 2004-03-17 | 2007-03-29 | Chiron Corp | Tratamiento de neumonia severa adquirida en comunidad por administracion del inhibidor de la via del factor tisular (tfpi). |
| AU2005243161A1 (en) * | 2004-05-11 | 2005-11-24 | Heptest Laboratories, Inc. | Compositions, kit and one-step method for monitoring compounds having anti-factor Xa and/or anti factor iia activities |
| JP2008507561A (ja) * | 2004-07-23 | 2008-03-13 | ザ ユニバーシティ オブ ロチェスター | 活性化プロテインcによる、脳内のプラスミノゲン活性化因子の不都合な作用の阻害 |
| US9107917B2 (en) * | 2005-05-13 | 2015-08-18 | The Feinstein Institute For Medical Research | Treatment of sepsis and inflammation with alpha2A adrenergic antagonists |
| ZA200800251B (en) * | 2005-06-24 | 2009-04-29 | Drugrecure Aps | Airway administration of tissue factor pathway inhibitor in inflammatory conditions affecting the respiratory track |
| WO2007004869A2 (en) | 2005-07-05 | 2007-01-11 | Biotempt B.V. | Treatment of tumors |
| EP1864692A1 (en) | 2006-06-07 | 2007-12-12 | Biotempt B.V. | Use of peptides for the control of radiation injury |
| US7785857B2 (en) * | 2006-08-31 | 2010-08-31 | Saint Louis University | Protein C variant |
| GR1005700B (el) * | 2006-09-01 | 2007-10-22 | (40%) ����� �������� | Τροπος αντιμετωπισης της 1ης φασης του εγκαυματοσσε μη σηπτικους ασθενεις με συνεχη ενδοφλεβια χορηγηση ενεργοποιημενης πρωτεινης-c για 48 ωρες με στοχο τη μειωση της τελικης εγκαυματικης βλαβης καιαυξηση της ταχυτητας επουλωσης κατα τα πρωτα επτα μετεγκαυματικα 24ωρα |
| EP2078074A4 (en) * | 2006-10-31 | 2011-09-28 | Scripps Research Inst | DOSAGE SCHEME OF ACTIVATED PROTEIN C AND ITS VARIANTS WITH REDUCED ANTICOAGULANT ACTIVITY |
| RU2445365C1 (ru) * | 2010-11-03 | 2012-03-20 | Общество с ограниченной ответственностью "Инновационный Центр "Новые Технологии и Материалы" (ООО "ИЦ Новтехмат") | Штамм гибридных культивируемых клеток mus musculus - продуцент моноклональных антител, специфичных к протеину с человека (варианты) |
| RU2490722C1 (ru) * | 2012-04-24 | 2013-08-20 | Федеральное государственное бюджетное учреждение науки Институт химической биологии и фундаментальной медицины Сибирского отделения Российской академии наук (ИХБФМ СО РАН) | Способ восстановления кровотока в регионе тромбированной вены в эксперименте |
| JP6273272B2 (ja) | 2012-07-04 | 2018-01-31 | ジージー バイオテック エルエルシー | 炎症性皮膚障害の治療 |
| ES2890623T3 (es) | 2014-04-16 | 2022-01-20 | Zz Biotech Llc | Uso del análogo de APC para curar heridas |
| DK3137102T3 (da) | 2014-04-16 | 2021-10-11 | Zz Biotech Llc | Apc til anvendelse til behandling af unormal kutan ardannelse |
| ES3060582T3 (en) | 2018-06-15 | 2026-03-27 | Alleima Striptech Ab | A duplex stainless steel strip and method for producing thereof |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4775624A (en) * | 1985-02-08 | 1988-10-04 | Eli Lilly And Company | Vectors and compounds for expression of human protein C |
| US5516650A (en) * | 1985-06-27 | 1996-05-14 | Zymogenetics, Inc. | Production of activated protein C |
| US5084274A (en) * | 1987-11-17 | 1992-01-28 | Scripps Clinic And Research Foundation | Inhibition of arterial thrombotic occlusion or thromboembolism |
| US4992373A (en) * | 1987-12-04 | 1991-02-12 | Eli Lilly And Company | Vectors and compounds for direct expression of activated human protein C |
| US5009889A (en) * | 1987-12-31 | 1991-04-23 | Oklahoma Medical Research Foundation | Treatment of dysfunctional vascular endothelium using activated protein C |
| GB8819607D0 (en) * | 1988-08-17 | 1988-09-21 | Wellcome Found | Novel combination |
| US4981952A (en) * | 1988-10-04 | 1991-01-01 | Eli Lilly And Company | Method for the purification of vitamin K-dependent proteins |
| US5254532A (en) * | 1989-06-26 | 1993-10-19 | Immuno Aktiengesellschaft Fur Chemisch-Medizinische Produkte | Preparation for treating and preventing thromboses and thromboembolic complications, use of such a preparation and a method of producing the same |
| IL97312A (en) * | 1990-02-23 | 1999-01-26 | Lilly Co Eli | A method of generating a polypeptide in an eukaryotic vector AND recombinant surrogate cell containing an enhanced transcriptional control unit based on the primary late adenovirus coefficient |
| AT402262B (de) * | 1991-06-20 | 1997-03-25 | Immuno Ag | Arzneimittel enthaltend aktiviertes protein c |
| MY110664A (en) * | 1992-05-21 | 1999-01-30 | Lilly Co Eli | Protein c derivatives |
| JP3434326B2 (ja) * | 1992-08-25 | 2003-08-04 | 財団法人化学及血清療法研究所 | 成人呼吸窮迫症候群(ards)予防、治療剤 |
| JP2825739B2 (ja) * | 1993-09-20 | 1998-11-18 | 帝人株式会社 | 急性肝不全治療剤 |
| JP3802104B2 (ja) * | 1995-05-31 | 2006-07-26 | 財団法人化学及血清療法研究所 | 脊髄損傷に伴う神経障害の予防・治療剤 |
| WO1997020043A1 (en) * | 1995-11-30 | 1997-06-05 | Zymogenetics, Inc. | Protein c production in transgenic animals |
| ZA983497B (en) * | 1997-04-28 | 1999-10-25 | Lilly Co Eli | Activated protein c formulations. |
| HUP0001237A3 (en) * | 1997-10-20 | 2002-01-28 | Lilly Co Eli | Methods for treating vascular disorders |
-
1998
- 1998-03-24 HU HU0001237A patent/HUP0001237A3/hu unknown
- 1998-09-28 US US09/161,900 patent/US6037322A/en not_active Expired - Lifetime
- 1998-10-14 JP JP2000516690A patent/JP3805981B2/ja not_active Expired - Fee Related
- 1998-10-14 KR KR1020007004170A patent/KR100798174B1/ko not_active Expired - Fee Related
- 1998-10-14 WO PCT/US1998/021723 patent/WO1999020293A1/en not_active Ceased
- 1998-10-14 EA EA200000445A patent/EA002496B1/ru not_active IP Right Cessation
- 1998-10-14 BR BR9812965-1A patent/BR9812965A/pt not_active Application Discontinuation
- 1998-10-14 ZA ZA9809385A patent/ZA989385B/xx unknown
- 1998-10-14 NZ NZ504026A patent/NZ504026A/xx not_active IP Right Cessation
- 1998-10-14 CN CN98810307A patent/CN1276726A/zh active Pending
- 1998-10-14 ID IDW20000683A patent/ID24901A/id unknown
- 1998-10-14 PL PL340096A patent/PL200515B1/pl not_active IP Right Cessation
- 1998-10-14 AU AU98040/98A patent/AU748417B2/en not_active Ceased
- 1998-10-14 TR TR2000/01059T patent/TR200001059T2/tr unknown
- 1998-10-14 CA CA002306983A patent/CA2306983A1/en not_active Abandoned
- 1998-10-14 TW TW087117061A patent/TWI225404B/zh not_active IP Right Cessation
- 1998-10-14 UA UA2000042259A patent/UA72194C2/uk unknown
- 1998-10-14 IL IL13571298A patent/IL135712A0/xx unknown
- 1998-10-14 HU HU0100025A patent/HU224901B1/hu not_active IP Right Cessation
- 1998-10-15 EP EP98308413A patent/EP0913156B1/en not_active Expired - Lifetime
- 1998-10-15 AT AT98308413T patent/ATE292979T1/de active
- 1998-10-15 ES ES98308413T patent/ES2239382T3/es not_active Expired - Lifetime
- 1998-10-15 SI SI9830773T patent/SI0913156T1/xx unknown
- 1998-10-15 DK DK98308413T patent/DK0913156T3/da active
- 1998-10-15 EP EP04005955A patent/EP1449537A3/en not_active Withdrawn
- 1998-10-15 PT PT98308413T patent/PT913156E/pt unknown
- 1998-10-15 DE DE69829721T patent/DE69829721T2/de not_active Expired - Lifetime
- 1998-10-15 MY MYPI98004703A patent/MY117655A/en unknown
- 1998-10-16 US US09/174,507 patent/US6008199A/en not_active Expired - Lifetime
-
1999
- 1999-10-08 US US09/415,876 patent/US6156734A/en not_active Expired - Lifetime
- 1999-10-08 US US09/415,761 patent/US6268344B1/en not_active Expired - Fee Related
- 1999-12-16 US US09/465,076 patent/US6268337B1/en not_active Expired - Fee Related
-
2000
- 2000-04-17 NO NO20002005A patent/NO20002005L/no not_active Application Discontinuation
- 2000-04-17 IL IL135712A patent/IL135712A/en not_active IP Right Cessation
- 2000-05-10 US US09/568,146 patent/US6489296B1/en not_active Expired - Fee Related
-
2001
- 2001-06-08 US US09/877,759 patent/US6426071B2/en not_active Expired - Fee Related
-
2004
- 2004-11-11 JP JP2004327938A patent/JP2005097313A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MY117655A (en) | Methods for treating hypercoagulable states or acquired protein c deficiency | |
| TR199802421T2 (tr) | Doku yenilenmesini düzenleyen maddeler. | |
| YU37304A (sh) | Specifični agensi koji vezuju humani angiopoetin-2 | |
| TR199802423T2 (tr) | Konsantre antikor terkibi. | |
| TR200100111T2 (tr) | Kalsiyum (3S)tetrahidro-3-furanil(1S,2R)-3- [[(4-aminofenil)sulfonil)(isobutil)amino] -1-benzil-2-(fosfonooksi) propilkarbamat | |
| EP2112161A3 (en) | Peptides that lower blood glucose levels | |
| IS4523A (is) | Speglunarskuggaefni, sem helst lengi í blóði, tilsjúkdómsgreininga | |
| EA200100939A1 (ru) | Продолжительно действующие инсулинотропные пептиды | |
| DE69922822D1 (de) | Rekombinante haarbehandlungsmittel | |
| TR200102784T2 (tr) | Diyabet tedavisi için ilaç | |
| TR200103819T2 (tr) | kanser tedavisinde ET743 terkipleri ve kullanımları | |
| TR199901949T2 (tr) | Lemfositik tümörler için çareler. | |
| ATE275966T1 (de) | Activin stimulator enthaltende pharmazeutische zusammensetzung | |
| ATE264340T1 (de) | Stabilisierung von gefriergetrocknetem kuchen | |
| FR2759701B1 (fr) | Utilisation des proteines ulip dans le diagnostic et la therapie des cancers et des syndromes neurologiques paraneoplasiques | |
| TR200001486T2 (tr) | Hiperkeratozlu deri hastalıklarının tedavisi için diol ve alfa-hidroksi asitten oluşan bir karışımın kullanılması | |
| DE60007973D1 (de) | Matrixprotein zusammensetzungen für pfropfung in nicht mineralisierten geweben | |
| TR200000416T2 (tr) | Neisseria loctoferrin bağlayıcı protein. | |
| TR199802270A2 (tr) | Sülfonamid-ikame etmis anelize 5-halka-bilesikleri. | |
| TR199800168A2 (tr) | Insan endoglin geni yükselticisi ve kullanimi. | |
| TR199700842T1 (tr) | Insan DNase I Varyantlari. | |
| FR2805540B1 (fr) | Nouvelle proteine ulip humaine et son utilisation dans le diagnostic et la therapie des cancers et des syndromes neurologiques paraneoplasiques | |
| EP1645270A3 (en) | Control of pain with endogenous cannabinoids | |
| NZ511034A (en) | Methods of downmodulating the immune response to therapeutic proteins | |
| NO984965D0 (no) | Komponent B som cicatrisant |